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Chlorinated cyanurates are added to swimming pools as disinfectants. In the presence of water, these
materials hydrolyze to yield cyanurate and hypochlorous acid. To evaluate the safety ofexposure to these
materials, a comprehensive testing program was undertaken. This review summarizes the results ofacute
and subchronic tests on chlorinated isocyanurates. Findings from acute, subchronic, reproduction, me-
tabolism, mutagenicity, andchronic/carcinogenicity tests oncyanurate are alsosummarized. Resultsfrom
these tests indicate that chlorinated isocyanurates are safe for use in swimming pools.
Introduction
Chlorinated derivatives of cyanurate and its salts
(chlorinated isocyanurates) are used as disinfectants
and algicides for swimming pools and cooling towers
and are regulated under provisions of the Federal In-
secticide, Fungicide and Rodenticide Act (FIFRA).
These compounds are also used as cleansing, bleaching,
and sanitizing agents in a variety of industrial appli-
cations. In the presence of water, chlorinated isocy-
anurates undergo hydrolysis to yield cyanurate and hy-
pochlorous acid; the latter compound is an active
bactericide and oxidizing agent. The cyanurate moiety
stabilizes hypochlorite in the presence ofsunlight, pro-
longing its disinfectant action in swimming pools.
The greatest potential for human exposure to cy-
anurate results from its use as a stabilizer ofhypochlo-
rite in swimming pools. Workers are also exposed to
chlorinated isocyanurates duringtheir manufacture and
packaging. To assess the risks from such exposure, a
variety of toxicology studies have been undertaken on
both chlorinated isocyanurates and cyanurate. This re-
view summarizes the results ofpublished toxicity stud-
ies and unpublished information developed by member
companies of The Industry ad hoc Committee on Iso-
cyanurates. All ofthe latter studies have been submit-
ted to the U.S. Environmental Protection Agency
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(EPA) to support the registration of these materials
under FIFRA.
Toxicology Studies on Chlorinated
lsocyanurates
Acute Toxicity
Dichloro- and trichloroisocyanurates are considered
no more than slightly toxic when administered as single
oral doses in rats. The LD50 values range from 600 to
1520 mg/kg. These materials are practically nontoxic
when applied as a single dose to rabbit skin, since the
dermal LD50 is consistently greater than 5000 mg/kg
(Monsanto, unpublished observations).
Chlorinated isocyanurates are generally corrosive
when applied to the rabbit eye and are severely irri-
tating or corrosive to rabbit skin when applied under
occluded conditions for 24 hr according to procedures
specified in the Federal Hazardous Substances Act
(FHSA). However, whentestedinthe4-hrDepartment
of Transportation (DOT) test, these materials are not
corrosive to rabbit skin (Monsanto, unpublished obser-
vations).
Subchronic Toxicity
Several inhalation studies have been conducted with
rats exposed to chlorinated isocyanurate dust. In an
early study that provided little information on experi-
mental details, the LC50 of trichloroisocyanurate dust
was reported to be 25 mg/m3 (1). As part ofthis inves-
tigation, 1.88 mg/m3 of the trichloroisocyanurate dust,HAMMOND ETAL.
administered 4 hr/day for 10 weeks, was reported to
have caused 30% mortality in rats.
Findings from more recent inhalation studies with
dichloroisocyanurate (2) and trichloroisocyanurate
(Monsanto, unpublished observations) did not agree
with these results. In these studies, groups of 10 male
and female CD rats were exposed separately to dichlo-
roisocyanurate and trichloroisocyanurate dusts at ana-
lytical exposure levels of approximately 3, 10, and 30
mg/m3 for 6 hr/day, 5 days/week for a total of4 weeks.
The mass median diameter ofchlorinated isocyanurate
dustsranged from2.1 to4.5 ,um(thematerialwassieved
to produce respirable dust particles). Contrary to the
earlier report, no mortality occurred in test animals in
either of these two studies. Adverse reactions were
observed in both ofthe recent studies in mid- and par-
ticularly high-dose animals during the exposure period
and included moist rales, nasal discharge, excess sali-
vation, lacrimation, and labored breathing. Because of
the deposition of dust on rat fur, the rats undoubtedly
ingested the test materials during preening. Apparent
treatment-related changes were observed in body
weights, organ weights, and certain clinical parameters
in mid- and, especially, high-dose animals. However,
these changes were not consistently observed in both
studies with the exception of increased lung weights,
which were observed in high-dose rats in both studies.
No remarkable gross pathologic changes were observed
in test animals sacrificed at the end ofthe study.
Microscopic examination oftissues fromhigh-dose an-
imals did not reveal any changes that were attributed
to treatment. (Animals administered trichloroisocy-
anurate dust were sacrificed 4 days after exposure had
terminated). The lower exposure concentration of3mg/
m3 was considered a no-effect level in both studies. The
approximate dailydose ofchlorinated isocyanurate dust
administered to rats in these 2 studies was 0.64 mg/kg
for the lowest exposure level. This dose was calculated
by assuming that total volume of air inspired by a rat
overa6 hrexposure period is 0.086 m3. The comparable
dose administered to a man (total volume ofairinspired
over8hris 10.4 im3) exposedto 0.5mg/m3 ofchlorinated
isocyanurate dust (a nonirritating level based on Mon-
santo workplace experience) can be estimated to be
about 0.074 mg/kg. This exposure level is lower by a
factor of8 than the no-effect exposure level in the rat.
Chlorinated isocyanurates have also been adminis-
tered in the feed and drinking water ofrats to evaluate
theirpotential subchronic toxicity. In one study, dichlo-
ro- and trichloroisocyanurate were administered sepa-
rately in drinking water to rats at concentrations of 0,
400, 1200, 4000, and 8000 ppm for 59 days (Industry ad
hoc Committee, unpublished observations). Each treat-
ment group consisted of five animals/sex/group except
controls (ten/sex). Mortality and adverse signs (labored
breathing, decreased activity) were observed in the
4000- and, especially, the 8000-ppm treatment groups
administered dichloro- or trichloroisocyanurate. Ani-
mals in these groups also exhibited moderate tomarked
reductions in body weight, and in food and water con-
sumption. (Waterconsumption was reduced in all treat-
ment groups presumably because of unpalatability.)
Hematology, clinical chemistry, and urinalysis param-
eters were evaluated for all treatment groups at the
end of the study. Most values were within historical
limits although urine volume and urinary creatinine
were reduced relative to control values for males ad-
ministered 8000 ppm chlorinated isocyanurates. At nec-
ropsy, animals administered 8000 ppm chlorinated iso-
cyanurates exhibited an increased inci'dence ofbleeding
in the gastrointestinal tract. (No histopathology was
performed on these animals.) With the exception ofre-
duced drinking water consumption, administration of
400 ppm (males) and 1200 ppm (females) of chlorinated
isocyanurates did not cause observable adverse effects
intest animals. Thisfindingtranslates tono-effectdoses
rangingfromapproximately 50to 130mg/kg, depending
on the sex ofthe animals.
In another subchronic study, dichloroisocyanurate
was incorporated in the diet of albino rats at concen-
trations of 0, 2000, 6000, and 12,000 ppm (Monsanto,
unpublished observations). Groups of 10 animals/sex
were administered these test diets for 13 weeks. Body
weights and food consumption were reduced in the two
highest treatment groups; mortality was limited to one
high-dosefemalerat. Urinaryandhematologicalparam-
eters were unaffected by any of the treatments. Rela-
tive kidney and liver weights were increased for mid-
and high-dose animals of both sexes. No dose-related,
gross or microscopic pathologic changes were observed
in any ofthe test animals. The no-effect level was con-
sidered to be 2000 ppm dichloroisocyanurate, which is
equivalent to a daily consumption of 100 mg/kg.
Teratology
Dichloroisocyanurate was administered by gavage to
pregnant dd strain mice at daily doses of0, 25, 100, and
400 mg/kg during the major period of organogenesis
(days 6-15 gestation) (3). Each treatment group con-
sisted of approximately 30 mice. Mortality occurred in
approximately 50% ofhigh-dose animals, because ofir-
ritationofthegastrointestinaltract. Bodyweightswere
reduced significantly for high-dose animals, and less so
for other groups.
There was no evidence that dichloroisocyanurate was
fetotoxic as the mean number of live/dead fetuses and
resorptions were comparable for control and treated
groups. The sex ratio and neonatal body weights were
also similar for all groups. There were no apparent dif-
ferences in the incidence of external malformations or
internal anomalies betweenthe variousgroups. A delay
in skeletal ossification was apparent in the fetuses from
high-dose animals. Ossification delays occur frequently
at doses that cause maternal toxicity and were not con-
sidered compound related. The incidence of other skel-
etalanomalieswascomparable forallgroups. Therewas
no evidence that dichloroisocyanurate was fetotoxic or
teratogenic in mice.
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Toxicology Studies on Cyanurate
Acute Toxicity
Cyanuric acid is practically nontoxic when adminis-
tered as a single oral or dermal dose. The oral LD50 in
rats is greater than 10,000 mg/kg; the dermal LD50 in
rabbits is greaterthan 7940 mg/kg. Accordingto FHSA
tests in rabbits, cyanuric acid is a slight eye irritant
(1.5/110) and nonirritatingto rabbit skin (Monsanto, un-
published observations).
Metabolism Studies
In a series ofmetabolism studies, cyanurate has been
shown to be readily eliminated from the body un-
changed. In one study, [14C] sodium cyanurate was ad-
ministered to rats at single doses of 5 mg/kg (oral, in-
travenous routes) and 500 mg/kg (oral route) (4). The
elimination half-life was 30 to 60 min at 5 mg/kg and 2.5
hr at 500 mg/kg. At the lower dose, the material was
completely absorbed and largely eliminated in urine. At
the higher dose, cyanurate was incompletely absorbed,
and a larger percentage of the dose was eliminated in
feces. Radioactivity remaining in tissues 7 days follow-
ing treatment was below the level ofdetection (0.1-1.0
Rg/g) for most tissues. Rats were also given 5 mg/kg!
day of unlabeled sodium cyanurate orally for 14 days
followed byasingle dose of5mg/kgradiolabeled sodium
cyanurate on day 15. Results from therepeattreatment
study showed no bioaccumulation and no significant
changes in disposition or metabolism compared to the
single exposure. There was no evidence that sodium
cyanurate was metabolized, as only unchanged cyan-
urate was found in exereta. These findings are sup-
ported by previous studies in the rat that also demon-
strated that cyanurate was poorly absorbed when
applied dermally (5).
The metabolic fate of sodium cyanurate was also in-
vestigated in the dog using the same experimental de-
sign (6). As in the rat, a lower dose of 5 mg/kg was
completely absorbed, whereas a bolus dose of 500 mg/
kg was only partially absorbed. Sodium cyanurate dis-
tributed into an apparent volume of distribution of 0.7
L/kg, which is somewhat greater than total body water
volume. The elimination half-life ranged from 1.5 to 2
hr; cyanurate was readily eliminated into urine un-
changed. Radioactivity remaining in tissues was below
the detection level (0.1-3.3 ,ug/g) for all sampling times
for both single and repeated dose administration. The
latter finding indicates that cyanurate does not bioac-
cumulate in tissues. There was no evidence that cy-
anurate was biodegraded in the dog, as no metabolites
were detected in exereta.
These findings appear to be applicable to humans,
since cyanurate was found to be rapidly and quantita-
tively eliminated unchanged in urine following oral
ingestion by volunteers (7).
Teratology Studies
Sodium cyanurate was administered to pregnant rats
and rabbits to evaluate its potential developmental tox-
icity. Pregnant Dutch beltedrabbits were given sodium
cyanurate by oral gavage during the major period of
organogenesis, days 6-18 of gestation. (FMC Corpo-
ration, unpublished observations.) Each group con-
sisted of9 to 10 pregnant rabbits with the exception of
the control and high-dose groups, which contained 20
to 21 pregnant rabbits. Sodium cyanurate was admin-
istered at daily dosages of50, 200, and 500 mg/kg (con-
trols were administered 20 mL/kg water). No com-
pound-related mortality or adverse reactions were
observed during the study. Slight body weight de-
creases were observed in mid- and high-dose animals
duringthetreatmentperiod. Aftertermination oftreat-
ment on day 18, compensatory weight gains occurred
inthesegroups. Noevidenceofdose-relatedfetotoxicity
was apparent in test animals examined on day 28 of
gestation. The mean number of live fetuses/dam and
sex ratio were essentially comparable for all groups.
Fetal body weights and crown/rump lengths were re-
duced slightly in high-dose animals when compared to
controls, although these values were within historical
limits for the laboratory. The mild reductions in body
weightgain and crown/rump lengths may have resulted
from the slight manifestations ofmaternal toxicity that
occurred during treatment. No evidence of a dose-re-
lated increase was observed in the incidence ofexternal
or internal malformations or skeletal anomalies in the
fetuses that were examined. It was concluded that so-
dium cyanurate was not fetotoxic or teratogenic in rab-
bits.
Sodium cyanurate was also administered by oral ga-
vage to pregnant CD rats during the major period of
organogenesis, days 6-15 ofgestation (8). The test ma-
terial was administered at doses of200, 1000, and 5000
mg/kg/dayto groups ofapproximately25pregnantrats.
Two sodium control groups of 25 rats each received
sodiumhippurateataconcentration sufficienttoprovide
a level of sodium cations equal to the sodium levels in
the 1000 and 5000 mg/kg cyanurate groups. Another
control group received the dosing vehicle, 4% aqueous
carboxymethyl cellulose, and an untreated control
group received only water by gavage.
No mortality, body weight changes or adverse re-
actions were observed in vehicle and untreated control
groups, the cyanurate groups, and the low-dose sodium
control groups. In the high-dose sodium control group,
11 animals died. Fetotoxic effects and an increased in-
cidence ofbentribs occurred inthefetusesfromfemales
administered the higher dose of sodium hippurate.
These effects were attributed to the maternal toxicity
observed in treated animals from this group.
The cesarean section observations and fetal exami-
nation data found no evidence that sodium cyanurate
was fetotoxic or teratogenic in the rat.
Reproductive Studies
To assess the long-term effects of sodium cyanurate
on reproductive performance, the test material was ad-
ministered to rats throughout three consecutive gen-
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erations (9). Sodium cyanurate was administered in the
drinking water at concentrations of400, 1200, and 5375
ppm (maximum water solubility) to groups of 12 male
and 24 female CD rats. Two control groups received
either tap water or sodium hippurate, which provided
an equivalent amount of sodium administered to high-
dose sodium cyanurate animals. Treatment was initi-
ated at 36 days of age for parents and continued for a
minimum of 100 days before mating. Parents were
mated to produce two litters (Fia, Flb). Weanlings from
theFlb litter were randomly selected as parents forthe
next generation and continued on treatment for an ad-
ditional 120 days. These animals were subsequently
mated to produce 2 litters (F2a, F2b). Weanlings from
the F2b litter were randomly selected as parents forthe
last generation. These animals were also administered
sodium cyanurate for 120 days and mated to produce
one litter (F3a). Randomly selected F3a progeny contin-
ued on cyanurate treatment for an additional 4 weeks
and were then sacrificed. Where possible, all progeny
from various matings were given a post mortem ex-
amination. Organ weight measurements and micro-
scopic examination of tissues (including gonads and
gross lesions) were carried out for all parental animals
i.e., selectedFib andF2b progeny andF3aoffspringthat
were sacrificed 4 weeks after weaning. No compound-
related mortality or adverse reactions were observed
during the study. Body weights and food consumption
were similar among all groups. There was no evidence
of dose-related or cross-generational changes in gesta-
tion length, litter size, pup survival to weaning, sex
ratio, or pup weight. No compound-related macroscopic
or microscopic pathologic changes or organ weight var-
iationswere apparentincyanuratetreated animalswith
one exception: a few high-dose cyanurate males did ex-
hibit calculi in the urinary bladder accompanied by mi-
croscopic evidence of epithelial hyperplasia or chronic
cystitis. These histologic changes were attributed to
chronic irritation by the calculi. It was concluded that
sodium cyanurate did not interfere with reproductive
performance in the rat when administered throughout
three consecutive generations.
Mutagenicity Studies
The mutagenic potential of sodium cyanurate was
evaluated using in vitro and in vivo tests (10). All in
vitro tests were carried out in the presence and absence
ofmetabolic activation. In each assay, the highest con-
centration tested generally exceeded the solubility of
monosodium cyanurate intheincubationmedium. Inthe
Salmonella microbial assay, sodium cyanurate was not
mutagenic in test strains TA 98, TA 100, TA 1535, and
TA 1537 up to a concentration of 10,000 ,ug/plate. So-
dium cyanurate did not induce forward mutations atthe
TK locus of L5178Y mouse lymphoma cells up to a con-
centration of 2000 pig/mL. No significant increases in
sister-chromatid exchanges were observed when so-
dium cyanurate was incubated with Chinese hamster
ovary cells at concentrations up to 1500 jxg/mL. In an
in vivo test, rats were administered sodium cyanurate
by gavage at single doses up to 5000 mg/kg and sacri-
ficed 24 and 48 hr after dosing. Bone marrow cells were
collected and examined for chromosomal aberrations.
At the time points examined, there was no evidence of
cyanurate-induced chromosomal aberrations inrat bone
marrow cells.
Subchronic Toxicity Studies
The subehronic toxicity ofsodium cyanurate has been
evaluated in both CD rats and B6C3F1 mice (Industry
ad hoc Committee, unpublished observations). In these
studies, sodium cyanurate was administered at concen-
trations up to 5375 ppm (maximum solubility limit for
cyanurate). At this concentration, the daily compound
consumption was 500 to 700 mg/kg for rats and 2000 to
2200 mg/kg for mice. The only adverse effect observed
in test animals was the finding of bladder calculi with
accompanying bladder epithelial hyperplasia in a few
high-dose male rats and mice. This finding was not un-
expected, since sodium cyanurate is not appreciably
water soluble and precipitates to form calculi in urine
at high concentrations. In a related study, sodium cy-
anurate was administered by gavage to F334 rats and
B6C3F1 mice at doses ranging from 500 to 6000 mg/kg/
dayfor 14weeks (NationalToxicologyProgram, private
communication). At the higher treatment levels, it was
unclear whether the test animals received the targeted
dose levels. At these levels, the test material precipi-
tated out of solution during dosing, making it difficult
to deliver the desired dose quantitatively. There was
no evidence of compound-related clinical changes and




Sodium cyanurate was administered in the drinking
water of CD rats and B6C3F1 mice for most of their
lifetime; e.g., 2 years (Industry ad hoc Committee, un-
published observations) (11). CD rats were randomly
assigned to treatments of 80 to 100/sex/group admin-
istered either 400, 1200, 2400, or 5375 ppm sodium cy-
anurate (maximum solubility level). An equal number
of control animals received either tap water or sodium
hippurate to provide an equivalent amount of sodium
administered to high-dose cyanurate animals. Animals
were observed regularly foradverse reactions and mor-
tality. Body weights and food and water consumption
weremeasuredatregularintervals. Clinicalparameters
(hematology, clinical chemistry, urinalysis) were eval-
uated for each group at 6, 12, 18, and 24 months. An-
imals used for measuring clinical parameters were sac-
rificed and examined for possible dose-related gross or
microscopic pathologic changes.
All animals in the study were given a post mortem
examination. Organ weights were recorded for animals
sacrificed at interim times and all animals surviving to
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terminal sacrifice. A comprehensive set of tissues was
examined microscopically for all high-dose and control
animals. Tissues identified as target organs for cyan-
urate-induced toxicity were examined from animals ad-
ministered lower doses of sodium cyanurate.
Treatment-related mortality was observed in some
(13/100) high-dose male animals that died on test during
the first 12 months of the study. Mortality was attrib-
uted to the development of calculi in the urinary tract
oftest animals. The urethra ofthe male rat is anatom-
ically moresusceptible toblockage fromcalculithanthat
ofthe female. The high concentrations ofcyanurate ad-
ministered in drinking water favored the development
of calculi in the urinary tract. Susceptible males that
could not pass calculi were thought to have succumbed
to secondary effects such as uremia from urinary tract
obstruction. Pathologic changes secondary to urinary
tract blockage were observed in some males that died
on test and in some that were sacrificed at 12 months.
These changes included hyperplasia, bleeding, and in-
flammation of the bladder epithelium, dilated and in-
flamed ureters, and renal tubular nephrosis. Slight tu-
bular nephrosis was also observed in a few high-dose
females during the first 12 months. These animals did
not exhibit bladder calculi. Inflammatory lesions in the
heart were also apparent in some ofthe high-dose males
that died early.
Duringthe last 12 months ofthe study, no treatment-
related mortality occurred. No evidence ofdose-related
gross or microscopic pathologic changes was apparent
in the tissues of test animals that died on test or that
were sacrificed during the last 12 months.
Body weights, food consumption, and clinical param-
eters were generally comparable for both control and
treated groups. Water consumption was increased for
the high-dose cyanurate and sodium control groups.
Survival and tumor incidence data were statistically
analyzed. Time-to-tumor data were analyzed for all be-
nign or malignant tumors, all tumors combined, and for
eachindividualtumortypethatappeared intwo ormore
animals in the high-dose group. A few statistically sig-
nificant variations were found in unadjusted trend or
homogeneity oflife table data. None ofthese variations
were considered to be biologically significant since they
resulted from several factors including an early death
among high dose males and an earlier discovery ofclin-
ically silent tumors. Based on the analysis performed,
it was concluded that sodium cyanurate was not carcin-
ogenic to male and female rats. During the first 12
months ofthe study, no adverse effects were observed
at 2400 ppm (average daily compound consumption was
154 mg/kg [males], 266 mg/kg [females]). During the
last 12 months, no adverse effects were observed at the
highest treatment level-5375 ppm (371 mg/kg [males],
634 mg/kg [females]).
In the chronic mouse study, sodium cyanurate has
been administered in drinking water at levels of 100,
400, 1200, and 5375 ppm to groups of 80 to 100 mice/
sex/treatment. Theexperimentaldesignissimilartothe
aforementioned chronic rat study. Final results for this
study are not yet available. However, during the first
18 months, no evidence of dose-related mortality was
found in any ofthe treatment groups. Slight reductions
in body weight were apparent at some study intervals
for high-dose female mice. No treatment-related
changes in clinical parameters have been apparent to
date with the possible exception of increased urinary
sodium levels in high-dose and sodium control animals.
No evidence ofcompound-related, gross or microscopic
pathologic changes has been apparent in the tissues of
animals examined up to 18 months.
Conclusions
Chlorinated isocyanurates are registered under
FIFRA for use in swimming pools. To assess the po-
tential human health effects from this use, an extensive
testing program was developed with the concurrence of
EPA scientists. The decision was made to undertake
the majority ofthe testing with sodium cyanurate (12).
The rationale for this decision is as follows. In pool
water, chlorinated isocyanurates hydrolyze to yield cy-
anurate and sodium hypochlorite as shown in equation
(1) (13,14):
2H20 + NaCl2C3N3O3 NaH2C3N3O3 + 2HOC1 (1)
In pool water, the chlorine level is maintained at con-
centrations from 1 to 3 ppm, which is comparable to the
levels used to disinfect drinking water (15). The avail-
able chlorine is eventually consumed, whereas the so-
dium cyanurate remains in the pool water. Over a pool
season, the concentration ofsodium cyanurate in water
will exceed that of available chlorine. In public pools,
the level of sodium cyanurate is normally controlled to
levels ranging from 30 to 100 ppm; in private pools, the
levels of cyanurate can attain higher concentrations
(16).
Exposure to high levels of chlorinated isocyanurates
may cause tissue irritation because of their ability to
release hypochlorite. Although hypochlorite can oxidize
and damage tissues at high concentrations, it was not
found to be carcinogenic when administered in drinking
water to F334 rats and B6C3F1 mice (17). Mice were
administered 500 to 1000 ppm sodium hypochlorite for
78 weeks and rats, 500 to 2000 ppm for 104 weeks.
The hydrolysis product of chlorinated isocyanurates
exhibited very little toxicity in the tests that have been
conducted. Cyanurate was not mutagenic in a battery
ofshort-term tests and was not teratogenic or fetotoxic
in the rabbit and rat. Moreover, cyanurate did not in-
terfere with reproductive performance in rats when ad-
ministered throughout three consecutive generations.
No significant toxicity was apparent in subchronic and
chronic toxicity studies in rats and mice. The only find-
ing of significance resulted from physical effects of cal-
culithatobstructedtheurinarytractofsusceptible male
rats causingmortality and secondary pathologic effects.
The low toxicity ofcyanurate is not unexpected, con-
sideringits chemical structure. Cyanuric acid is a mem-
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ber of the symmetrical triazine family. It is produced
by the polymerization ofurea to yield 2,4,6-trihydroxy-
s-triazine. Compounds structurally related to cyanuric
acid are quite stable invivo as they are resistant toring
hydrolysis. For example, hydrolysis of the oxopyrimi-
dine ring ofbarbiturates occurs to only a minor extent
in man and animals. Cyanurate is also resistant to ring
hydrolysis or further degradation, as it is readily elim-
inated unchanged in excreta (primarily urine) following
its administration to rats, dogs, and man.
The absence of significant cyanurate-induced effects
in a variety of studies designed to measure different
toxic endpoints indicatesthatthereis asubstantial mar-
gin ofsafety for human exposure to cyanurate in swim-
mingpools. A70-kgadultwhoswimsinapoolcontaining
100 ppm cyanurate might ingest 1 to 2 cups of water,
resulting in an exposure of up to 0.7 mg/kg. This level
of exposure is far below the no-effect level that lies
between 154 and 371 mg/kg for male rats, which are
more susceptible than females to developing calculi. If
a swimmer were exposed to higher levels ofcyanurate,
there would still be a substantial margin of safety.
Swimmers are intermittently exposed to cyanurate (un-
like the laboratory animals in chronic studies, which
were continuously exposed). Since cyanurate is rapidly
eliminated from the body, there would not be an op-
portunity for it to build up in urinary tract tissues at
high enough levels to form calculi. The evidence to date
indicates that cyanurate is safe for its intended use in
swimming pools and other applications.
NOTE ADDED IN PROOF: Final results ofthe chronic
mouse study were recently received. Sodium cyanurate
was not carcinogenic to mice and did not produce defin-
itive treatment-related effects at any ofthe levels tested.
The work described in this paper was not funded by EPA and no
official endorsement should be inferred. The previously unpublished
information cited in this review was supported by the Industry ad
hoc Committee on Isocyanurates. Participating companies include
Monsanto Company, Olin Corporation, Nissan Chemical Industries,
Shikoku Chemicals Corporation, ICI Americas Inc., and FMC Cor-
poration. Inquiries regarding this information should be directed to
Monsanto Company.
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